1-855-378-42281-855-378-4228
One of the out-patient rehab alternatives for individuals in Timblin battling with opioid abuse and addiction is opioid maintenance therapy. Some facilities and doctors are authorized to dispense specific meds to opioid dependent people, many that are opioid-based themselves and are addiction. In low amounts however, the user doesn't feel high and also doesn't have intense cravings and is not experiencing opioid withdrawal. Methadone is the first med administered for this reason, but there are a few more choices currently to select from.
Methadone is an opioid and is meant to be taken at an out-patient medical center certified to administer the drug, that is taken on a daily basis as a pill or liquid. The cost of the drug is about $150 per month. Buprenorphine is also an opioid based med, and is a pill often taken every other day. But unlike Methadone that is only be administered in highly structured medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The price monthly of buprenorphine is approximately $300.00 per month for the generic version of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, that is a med which reverses the effects of opioids. An individual taking this version of the drug, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken daily, and is priced approximately $450 monthly. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other medications aforementioned it is an opiate blocker and is not an opiate. A person has the choice to take this drug as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents an individual from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 per month.
For All Drug and Alcohol Rehab Programs In Timblin, Click Here.
